E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

NCT01401530 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-Cell Lymphoma

Interventions

BIOLOGICAL: denileukin diftitox (E7777)

Sponsor

Eisai Co., Ltd.